# Jasper Therapeutics Jasper Therapeutics is an Asset Manager based in Redwood City, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Redwood City, United States - **Region:** North America - **Address:** Redwood City, CA, United States - **Founded:** 2019 - **Assets under management:** Undisclosed - **Website:** jaspertherapeutics.com ## Regulatory record - **Reports private funds:** No ## About Jasper Therapeutics was founded in 2019 to develop targeted conditioning agents that clear space for hematopoietic stem-cell transplants — an approach designed to make these procedures safer and more broadly applicable. The company traces its platform to research at Stanford University and launched as a spinout of Amgen's former inflammation division. Ronald Martell, previously CEO of Achieve Life Sciences and an executive at Genentech and Roche, joined as president and CEO at inception. The firm concentrates exclusively on the conditioning phase of stem-cell transplant, specifically with its lead antibody briquilimab, which targets c-Kit (CD117) to deplete diseased stem cells. This differs from the bifurcated strategies typical of early-stage immuno-oncology companies; Jasper is betting that a single mechanism can unlock curative gene therapies, immune reset in autoimmune disease, and improved outcomes in bone marrow transplant. The company has disclosed clinical-stage programs in chronic spontaneous urticaria and lower-risk myelodysplastic syndromes, with data readouts anticipated in the 2025–2026 window. It maintains a lean, in-house development engine while relying on academic partnerships and contract manufacturing, most notably with Stanford and partners in the CSTR and BEACON trials. Jasper became a public company via a reverse merger in 2022 — absorbing the shell of a dried-up SPAC — and then completed a $103 million underwritten public offering in March 2023. The executive team includes CMO Edwin Tucker, who previously held senior clinical roles at Amgen and holds an MD from Cambridge, and COO/CFO Jeet Mahal, a veteran of Genentech finance. A notable operational milestone came in January 2024 when the firm centralized manufacturing for briquilimab under a long-term supply arrangement with a European CDMO, which resolved a prior reliance on fragmented academic batch production (per SEC filings, 2024). The company operates as a classic biotechnology platform with a single New York Stock Exchange listing (ticker: JSPR), no philanthropic carve-out, and no parallel venture-arm structure. What separates Jasper from the dozens of other pre-revenue clinical-stage biotechs is its structural concentration on the conditioning niche. It does not own a gene therapy, a cell therapy, or a diagnostic. Instead, briquilimab is positioned as the overlaying conditioner for other companies' curative therapies — a role that makes licensing partnerships, rather than pipeline breadth, the firm's commercial pivot. ## Sectors - Healthcare Services ## People - Ronald Martell — President and Chief Executive Officer - Edwin Tucker — Chief Medical Officer - Jeet Mahal — Chief Operating Officer and Chief Financial Officer ## Questions ### What is Jasper Therapeutics's lead clinical asset and how does it work? The firm's lead asset is briquilimab, a monoclonal antibody that targets c-Kit (CD117) found on hematopoietic stem cells. By blocking this receptor, briquilimab depletes diseased stem cells from the bone marrow, creating an empty niche for donor or gene-corrected cells. Jasper is pursuing this mechanism across multiple indications, including chronic spontaneous urticaria and myelodysplastic syndromes, under a single-platform clinical development model. ### Who is in charge of clinical development and what is his background? Edwin Tucker, the chief medical officer, leads clinical development. Tucker holds an MD from the University of Cambridge and has previously led a Phase 3 oncology program at Amgen. His experience spans immuno-oncology and bone-modifying agents, which are directly relevant to the hematopoietic stem-cell platform Jasper is building. ### How is Jasper Therapeutics financed, and when did it become a public company? Jasper became a public company in 2022 via a reverse merger with a SPAC vehicle, and subsequently raised approximately $103 million in a March 2023 underwritten public offering. As a pre-revenue, clinical-stage company, it has historically funded operations through public equity raises rather than venture capital, which gives it a different capital-structure profile from privately backed biotechs. ### What makes Jasper's strategy different from other stem-cell therapy companies? Jasper does not develop cell or gene therapies. It focuses exclusively on conditioning — preparing the patient's bone marrow to accept a transplant — making its asset a potential pairing partner for other curative therapies rather than a competitor. This places the firm at the front end of the hematopoietic stem-cell transplant workflow, where it can collaborate with gene-therapy developers without the overhead of owning a cell-manufacturing capability. ### Where is Jasper Therapeutics located and does it have any other facilities? Jasper is headquartered in Redwood City, California. It does not maintain additional physical offices, but manages a distributed clinical-trial network in the U.S. and Europe. In January 2024, the firm consolidated its manufacturing with a single European contract development and manufacturing organization, per SEC filings, centralizing the supply chain that was previously run through academic facilities. ## Related profiles - [Oncotelic Therapeutics](https://altss.com/profile/oncotelic-therapeutics-inc) - [Celularity](https://altss.com/profile/celularity-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/jasper-therapeutics-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology